Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4NIH 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Non-Small-Cell Lung 59Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lung Neoplasms 25Squamous Cell Carcinoma of Head and Neck 20Melanoma 19Neoplasm Metastasis 18Neoplasms 16Endometrial Neoplasms 14Colorectal Neoplasms 14Breast Neoplasms 14Triple Negative Breast Neoplasms 12Ovarian Neoplasms 11Head and Neck Neoplasms 9Carcinoma, Renal Cell 8Pancreatic Neoplasms 7Carcinoma, Transitional Cell 7Urinary Bladder Neoplasms 6Recurrence 5Lymphoma 5Hodgkin Disease 5Esophageal Neoplasms 4Carcinoma 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Prostatic Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × pembrolizumab × 30 days × Clear all
NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07218380 2026-06-03

FORAGER-2

Eli Lilly and Company

Phase 3 Recruiting
450 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03924856 2026-05-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Completed
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

Phase 2 Active not recruiting
375 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
111 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05614739 2026-05-19

FORAGER-1

Eli Lilly and Company

Phase 1 Recruiting
535 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡